The Value of an Optimized Clinical Data Strategy: How Small Changes Can Make a Big Difference

In clinical trials, high-quality data is essential. It drives the drug development decision-making process and is a requirement for regulatory approval. But while most sponsors develop data strategies for their clinical programs, it often happens late in the development process.

Prioritizing the planning of your clinical data strategy early on — rather than late in the development process or only on a trial-by-trial basis — can help define the approach to data collection, storage, and analysis; can ensure the design, build, and delivery is fit for purpose; can address data issues proactively and in real time, minimizing delays and improving data quality; and can help ensure decision-makers will approve the new therapy.

Our eBook, Discover the Value of an Optimized Clinical Data Strategy: How Small Changes to Your Data Strategy Can Make a Big Difference to Your Chances of Success in Clinical Development, discusses key elements of clinical data strategy for the duration of the development program. It outlines best practices and shares insights from industry experts, including:

1. Key Considerations in Planning Your Clinical Data Strategy
   
   
2. The Value of Planning a Program-Wide Data Strategy, Earlier
   
   
3. Planning Phase 1 — Mitigating Unknown Risks Before They Arise
   
   
4. Planning Phase 2 — Ensuring a High-Quality Evidence Package
   
   
5. Top Tips on Optimizing Your Data Strategy Planning

To learn more, click to download Discover the Value of an Optimized Clinical Data Strategy:

Discover the Value of an Optimized Clinical Data Strategy is featured as part of our winter Weekend Reads series, which includes complimentary publications on a variety of topics on clinical trial design and data science. Subscribe to our weekly newsletter below and never miss a post!

Read more from Perspectives on Enquiry and Evidence:

Sorry no results please clear the filters and try again

Presenting Clinical Data for Regulatory Submission: A Stats Perspective

Data submissions are very regulated, but every drug and drug development are different. Therefore, the data presented..

Read more

Preparing Your Integrated Summaries of Safety and Effectiveness: Best Practices

Written by Angelo Tinazzi and Florence Le Maulf Integrated Summaries of Safety (ISS) and Integrated Summaries of..

Read more

Reducing Independent Data Monitoring Committee Timelines: A Focus on Formal Interim Analyses

As the pressure to reduce timelines rises across the industry, independent data monitoring committees (IDMCs) — which..

Read more